Erste Asset Management GmbH reduced its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 53.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,000 shares of the biopharmaceutical company’s stock after selling 125,800 shares during the quarter. Erste Asset Management GmbH’s holdings in Ocular Therapeutix were worth $1,353,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in OCUL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 5,156 shares in the last quarter. Caxton Associates LLP bought a new stake in Ocular Therapeutix during the first quarter worth $248,000. Creative Planning raised its position in Ocular Therapeutix by 21.5% during the second quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 3,791 shares in the last quarter. JPMorgan Chase & Co. raised its position in Ocular Therapeutix by 110.8% during the second quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock worth $6,608,000 after acquiring an additional 374,269 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in Ocular Therapeutix by 57.9% during the second quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 6,855 shares in the last quarter. 59.21% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, insider Pravin Dugel sold 21,156 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the completion of the sale, the insider owned 2,597,170 shares of the company’s stock, valued at $21,296,794. This represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 28,999 shares of company stock worth $237,792 over the last three months. Corporate insiders own 2.30% of the company’s stock.
Ocular Therapeutix Trading Up 3.2%
Analyst Upgrades and Downgrades
Several analysts have issued reports on OCUL shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. William Blair reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Monday, March 2nd. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Chardan Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.
Check Out Our Latest Report on OCUL
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
Featured Stories
- Five stocks we like better than Ocular Therapeutix
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
